Type i interferons: Key players in normal skin and select cutaneous malignancies

Dermatology Research and Practice

Volumn 2014, Issue , 2014, Pages

  Ismail, Aimen ^a   Yusuf, Nabiha ^b  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; INTERFERON;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BASAL CELL CARCINOMA; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CUTANEOUS MELANOMA; HUMAN; IMMUNE FUNCTION TEST; IMMUNOMODULATION; INVESTIGATIVE PROCEDURES; KERATINOCYTE; MELANOCYTE; NONHUMAN; SKIN CARCINOGENESIS; SKIN CARCINOMA;

EID: 84893169166     PISSN: None     EISSN: 16876113     Source Type: Journal    
DOI: 10.1155/2014/847545     Document Type: Article

References (74)

1. Kim K. H., Yavel R. M., Gross V. L., Brody N., Intralesional interferon 2b in the treatment of basal cell carcinoma and squamous cell carcinoma: revisited. Dermatologic Surgery 2004 30 1 116 120 2-s2.0-0842333115 10.1111/j.1524-4725.2004.30020.x (Pubitemid 38174043)
2. Good L. M., Miller M. D., High W. A., Intralesional agents in the management of cutaneous malignancy: a review. Journal of the American Academy of Dermatology 2011 64 2 413 422 2-s2.0-78751576020 10.1016/j.jaad.2009.12.013
3. Tarhini A. A., Gogas H., Kirkwood J. M., IFN-in the treatment of melanoma. Journal of Immunology 2012 189 8 3789 3793 10.4049/jimmunol.1290060
4. Clifford J. L., Menter D. G., Yang X., Walch E., Zou C., Clayman G. L., Schaefer T. S., El-Naggar A. K., Lotan R., Lippman S. M., Expression of protein mediators of type I interferon signaling in human squamous cell carcinoma of the skin. Cancer Epidemiology Biomarkers and Prevention 2000 9 9 993 997 2-s2.0-0033801557
5. Clifford J. L., Walch E., Yang X., Xu X., Alberts D. S., Clayman G. L., El-Naggar A. K., Lotan R., Lippman S. M., Suppression of type I interferon signaling proteins is an early event in squamous skin carcinogenesis. Clinical Cancer Research 2002 8 7 2067 2072 2-s2.0-0035992269 (Pubitemid 34753575)
6. Bekisz J., Baron S., Balinsky C., Morrow A., Zoon K. C., Antiproliferative properties of type I and type II interferon. Pharmaceuticals 2010 3 4 994 1015 2-s2.0-77952214698 10.3390/ph3040994
7. Ascierto P. A., Gogas H. J., Grob J. J., Algarra S. M., Mohr P., Hansson J., Hauschild A., Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review. Critical Reviews in Oncology/Hematology 2013 85 2 149 161 10.1016/j.critrevonc.2012.07.004
8. Mocellin S., Lens M. B., Pasquali S., Pilati P., Chiarion S. V., Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database of Systematic Reviews 2013 6 CD008955
9. Bostanci S., Kocyigit P., Alp A., Erdem C., Gürgey E. G., Treatment of basal cell carcinoma located in the head and neck region with intralesional interferon-2a evaluation of long-term follow-up results. Clinical Drug Investigation 2005 25 10 661 667 2-s2.0-24944590701 10.2165/00044011-200525100- 00005 (Pubitemid 41330308)
10. Doan B., Harmanyeri Y., Balolu H., Öztek I., Intralesional alfa-2a interferon therapy for basal cell carcinoma. Cancer Letters 1995 91 2 215 219 2-s2.0-0029068096 10.1016/0304-3835(95)03741-E
11. Grob J. J., Collett A. M., Munoz M. H., Bonerandi J. J., Treatment of large basal-cell carcinomas with intralesional interferon-alpha 2a. Lancet 1988 1 8590 878 879 2-s2.0-0023928771 (Pubitemid 18092416)
12. Edwards L., Berman B., Rapini R. P., Whiting D. A., Tyring S., Greenway H. T., Eyre S. P., Tanner D. J., Taylor E. L., Peets E., Smiles K. A., Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy. Archives of Dermatology 1992 128 11 1486 1489 2-s2.0-0026490144 10.1001/archderm.128.11.1486
13. DiLorenzo P. A., Goodman N., Lansville F., Markel W., Regional and intralesional treatment of invasive basal cell carcinoma with interferon alfa-n2b. Journal of the American Academy of Dermatology 1994 31 1 109 111 2-s2.0-0028308690 (Pubitemid 24198175)
14. LeGrice P., Baird E., Hodge L., Treatment of basal cell carcinoma with intralesional interferon alpha-2a. New Zealand Medical Journal 1995 108 1000 206 207 2-s2.0-0029057234
15. Alpsoy E., Yilmaz E., Başaran E., Yazar S., Comparison of the effects of intralesional interferon alfa-2a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma. Journal of Dermatology 1996 23 6 394 396 2-s2.0-0030056075 (Pubitemid 26234863)
16. McDonald R. R., Georgouras K., Treatment of basal cell carcinoma with intralesional interferon alpha: a case report and literature review. Australasian Journal of Dermatology 1992 33 2 81 86 2-s2.0-0027027656
17. Yaar M., Karassik R. L., Schnipper L. E., Gilchrest B. A., Effects of alpha and beta interferons on cultured human keratinocytes. Journal of Investigative Dermatology 1985 85 1 70 74 2-s2.0-0021844981 (Pubitemid 15069718)
18. Nickoloff B. J., Basham T. Y., Merigan T. C., Morhenn V. B., Antiproliferative effects of recombinant -and γ -interferons on cultured human keratinocytes. Laboratory Investigation 1984 51 6 697 701 2-s2.0-0021702027 (Pubitemid 15188782)
19. Bielenberg D. R., McCarty M. F., Bucana C. D., Yuspa S. H., Morgan D., Arbeit J. M., Ellis L. M., Cleary K. R., Fidler I. J., Expression of interferon- β is associated with growth arrest of murine and human epidermal cells. Journal of Investigative Dermatology 1999 112 5 802 809 2-s2.0-0032925239 10.1046/j.1523-1747.1999.00566.x (Pubitemid 29220726)
20. Krasagakis K., Garbe C., Kruger S., Orfanos C. E., Effects of interferons on cultured human melanocytes in vitro: interferon-beta but not-alpha or -gamma inhibit proliferation and all interferons significantly modulate the cell phenotype. Journal of Investigative Dermatology 1991 97 2 364 372 2-s2.0-0025866981
21. Stout A. J., Gresser I., Thompson W. D., Inhibition of wound healing in mice by local interferon/ β injection. International Journal of Experimental Pathology 1993 74 1 79 85 2-s2.0-0027501982 (Pubitemid 23076983)
22. McCarty M. F., Bielenberg D., Donawho C., Bucana C. D., Fidler I. J., Evidence for the causal role of endogenous interferon-/ β in the regulation of angiogenesis, tumorigenicity, and metastasis of cutaneous neoplasms. Clinical and Experimental Metastasis 2002 19 7 609 615 2-s2.0-0036457022 10.1023/A:1020923326441 (Pubitemid 35454571)
23. Niederwieser D., Aubock J., Troppmair J., Herold M., Schuler G., Boeck G., Lotz J., Fritsch P., Huber C., IFN-mediated induction of MHC antigen expression on human keratinocytes and its influence on in vitro alloimmune responses. Journal of Immunology 1988 140 8 2556 2564 2-s2.0-0023941472
24. Nickoloff B. J., Basham T. Y., Merigan T. C., Morhenn V. B., Immunomodulatory and antiproliferative effect of recombinant alpha, beta, and gamma interferons on cultured human malignant squamous cell lines, SCL-1 and SW-1271. Journal of Investigative Dermatology 1985 84 6 487 490 2-s2.0-0021824230 (Pubitemid 15053202)
25. Naito Y., Baba T., Suzuki H., Uyeno K., The antagonistic effect of interferon-beta on the interferon-gamma-induced expression of HLA-DR antigen in a squamous cell carcinoma line. Journal of Experimental Pathology 1992 6 1-2 75 87 2-s2.0-0026477955
26. Shin D. M., Glisson B. S., Khuri F. R., Clifford J. L., Clayman G., Benner S. E., Forastiere A. A., Ginsberg L., Liu D., Lee J. J., Myers J., Goepfert H., Lotan R., Hong W. K., Lippman S. M., Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. Journal of Clinical Oncology 2002 20 2 364 370 2-s2.0-0037080124 10.1200/JCO.20.2.364 (Pubitemid 34072517)
27. Rodriguez-Villaueva J., McDonnell T. J., Induction of apoptotic cell death in non-melanoma skin cancer by interferon-International Journal of Cancer 1995 61 1 110 114 2-s2.0-0028969543 10.1002/ijc.2910610119
28. Clifford J. L., Yang X., Walch E., Wang M., Lippman S. M., Dominant negative signal transducer and activator of transcription 2 (STAT2) protein: stable expression blocks interferon alpha action in skin squamous cell carcinoma cells. Molecular Cancer Therapeutics 2003 2 453 459
29. Urosevic M., Oberholzer P. A., Maier T., Hafner J., Laine E., Slade H., Benninghoff B., Burg G., Dummer R., Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-? Clinical Cancer Research 2004 10 15 4959 4970 2-s2.0-4143061382 10.1158/1078-0432.CCR-04-0193 (Pubitemid 39099769)
30. Zagon I. S., McLaughlin P. J., Opioids and the apoptotic pathway in human cancer cells. Neuropeptides 2003 37 2 79 88 2-s2.0-0037775859 10.1016/S0143-4179(03)00007-6 (Pubitemid 37421490)
31. Buechner S. A., Wernli M., Harr T., Hahn S., Itin P., Erb P., Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide. Journal of Clinical Investigation 1997 100 11 2691 2696 2-s2.0-0031442027 (Pubitemid 28007536)
32. Kim J., Modlin R. L., Moy R. L., Dubinett S. M., McHugh T., Nickoloff B. J., Uyemura K., IL-10 production in cutaneous basal and squamous cell carcinomas: a mechanism for evading the local T cell immune response. Journal of Immunology 1995 155 4 2240 2247 2-s2.0-0029121415
33. Yamamura M., Modlin R. L., Ohmen J. D., Moy R. L., Local expression of antiinflammatory cytokines in cancer. Journal of Clinical Investigation 1993 91 3 1005 1010 2-s2.0-0027474413 (Pubitemid 23095275)
34. Buechner S. A., Intralesional interferon alfa-2b in the treatment of basal cell carcinoma: immunohistochemical study on cellular immune reaction leading to tumor regression. Journal of the American Academy of Dermatology 1991 24 5 731 734 2-s2.0-0025809190
35. Mozzanica N., Cattaneo A., Boneschi V., Brambilla L., Melotti E., Finzi A. F., Immunohistological evaluation of basal cell carcinoma immunoinfiltrate during intralesional treatment with alpha2-interferon. Archives of Dermatological Research 1990 282 5 311 317 2-s2.0-0025351873 10.1007/BF00375725 (Pubitemid 20229793)
36. Johns T. G., Mackay I. R., Callister K. A., Hertzog P. J., Devenish R. J., Linnane A. W., Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon β Journal of the National Cancer Institute 1992 84 15 1185 1190 2-s2.0-0026742542
37. Roh M. R., Zheng Z., Jeung H. C., Rha S. Y., Chung K. Y., Difference of interferon-alpha and interferon-beta on melanoma growth and lymph node metastasis in mice. Melanoma Research 2013 23 2 114 124 10.1097/CMR. 0b013e32835e7713
38. Garbe C., Krasagakis K., Zouboulis C. C., Schroder K., Kruger S., Stadler R., Orfanos C. E., Antitumor activities of interferon alpha, beta, and gamma and their combinations on human melanoma cells in vitro: changes of proliferation, melanin synthesis, and immunophenotype. Journal of Investigative Dermatology 1990 95 6 231S 237S 2-s2.0-0025605058
39. Bölling B., Fandrey J., Frosch P. J., Acker H., VEGF production, cell proliferation and apoptosis of human IGR 1 melanoma cells under nIFN-/ β and rIFN- γ treatment. Experimental Dermatology 2000 9 5 327 335 2-s2.0-0033832275 10.1034/j.1600-0625.2000.009005327.x
40. Horikoshi T., Fukuzawa K., Hanada N., Ezoe K., Eguchi H., Hamaoka S., Tsujiya H., Tsukamoto T., In vitro comparative study of the antitumor effects of human interferon-β and γ on the growth and invasive potential of human melanoma cells. Journal of Dermatology 1995 22 9 631 636 2-s2.0-0029144004
41. Schaber B., Mayer P., Schreiner T., Rassner G., Fierlbeck G., Anti-proliferative activity of natural interferon-alpha, isotretinoin and their combination varies in different human melanoma cell lines. Melanoma Research 1994 4 5 321 326 2-s2.0-0028034156 10.1097/00008390-199410000-00009 (Pubitemid 24323267)
42. Kubo H., Ashida A., Matsumoto K., Kageshita T., Yamamoto A., Saida T., Interferon- β therapy for malignant melanoma: the dose is crucial for inhibition of proliferation and induction of apoptosis of melanoma cells. Archives of Dermatological Research 2008 300 6 297 301 2-s2.0-46649113134 10.1007/s00403-008-0841-6
43. Lossino C., Wines B. D., Johns T. G., Mackay I. R., Natural killer cell activity against cultured melanoma cells: a dye-reduction technique with studies on augmented activity by interferon subtypes. Natural Immunity 1992 11 4 215 224 2-s2.0-0026668049
44. Chawla-Sarkar M., Leaman D. W., Borden E. C., Preferential induction of apoptosis by interferon (IFN)- β compared with IFN-2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clinical Cancer Research 2001 7 6 1821 1831 2-s2.0-0034895641 (Pubitemid 32708654)
45. Schiller J. H., Willson J. K. V., Bittner G., Wolberg W. H., Hawkins M. J., Borden E. C., Antiproliferative effects of interferons on human melanoma cells in the human tumor colony-forming assay. Journal of Interferon Research 1986 6 6 615 625 2-s2.0-0022885397 (Pubitemid 17024427)
46. Köpf J. I., Hanson C., Delle U., Weimarck A., Stierner U., Action of interferonand β on four human melanoma cell lines in vitro. Anticancer Research 1996 16 2 791 798 2-s2.0-0029994487 (Pubitemid 26182011)
47. Chawla-Sarkar M., Leaman D. W., Jacobs B. S., Borden E. C., IFN- β pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis. Journal of Immunology 2002 169 2 847 855 2-s2.0-0037100434 (Pubitemid 34753441)
48. Borden E. C., Jacobs B., Hollovary E., Rybicki L., Elson P., Olencki T., Triozzi P., Gene regulatory and clinical effects of interferon β in patients with metastatic melanoma: a phase II trial. Journal of Interferon and Cytokine Research 2011 31 5 433 440 2-s2.0-79955768337 10.1089/jir.2010.0054
49. Raig E. T., Jones N. B., Varker K. A., Benniger K., Go M. R., Biber J. L., Lesinski G. B., Carson W. E. III, VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines. Journal of Interferon and Cytokine Research 2008 28 9 553 561 2-s2.0-51349135746 10.1089/jir.2008.0118
50. Håkansson A., Gustafsson B., Krysander L., Håkansson L., Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. The British Journal of Cancer 1996 74 5 670 676 2-s2.0-0029738930 (Pubitemid 26300755)
51. Håkansson A., Gustafsson B., Krysander L., Håkansson L., Effect of IFN-on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma. Journal of Interferon and Cytokine Research 1998 18 1 33 39 2-s2.0-0031881714 (Pubitemid 28084074)
52. Moschos S. J., Edington H. D., Land S. R., Rao U. N., Jukic D., Shipe-Spotloe J., Kirkwood J. M., Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. Journal of Clinical Oncology 2006 24 19 3164 3171 2-s2.0-33745989541 10.1200/JCO.2005.05.2498 (Pubitemid 46638955)
53. + T cells and monocyte/dendritic cell precursors. Cancer Research 2006 66 9 4943 4951 2-s2.0-33646400810 10.1158/0008-5472.CAN-05-3396
54. Mohty A. M., Grob J. J., Mohty M., Richard M. A., Olive D., Gaugler B., Induction of IP-10/CXCL10 secretion as an immunomodulatory effect of low-dose adjuvant interferon-alpha during treatment of melanoma. Immunobiology 2010 215 2 113 123 2-s2.0-71849085783 10.1016/j.imbio.2009.03.008
55. Tsavaris N., Baxevanis C., Kosmidis P., Papamichael M., The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon2b. Cancer Immunology Immunotherapy 1996 43 2 94 102 2-s2.0-0029851566 10.1007/s002620050308 (Pubitemid 26385226)
56. Fujimura T., Okuyama R., Ohtani T., Ito Y., Haga T., Hashimoto A., Aiba S., Perilesional treatment of metastatic melanoma with interferon- β Clinical and Experimental Dermatology 2009 34 7 793 799 2-s2.0-70349507952 10.1111/j.1365-2230.2009.03207.x
57. Nakayama J., Toyofuku K., Urabe A., Taniguchi S., Hori Y., A combined therapeutic modality with hyperthermia and locally administered rIFN- β inhibited the growth of B16 melanoma in association with the modulation of cellular infiltrates. Journal of Dermatological Science 1993 6 3 240 246 2-s2.0-0027741312 10.1016/0923-1811(93)90045-Q (Pubitemid 24024415)
58. Håkansson A., Gustafsson B., Krysander L., Bergenwald C., Sander B., Håkansson L., Effect of interferon-on the expression of tumour necrosis factor-by metastatic malignant melanoma in vivo. Melanoma Research 1997 7 2 139 145 2-s2.0-0031004787 (Pubitemid 27240135)
59. Hofmann M. A., Kiecker F., Kuchler I., Kors C., Trefzer U., Serum TNF-a, B2M and sIL-2R levels are biological correlates of outcomes in adjuvant IFN-a2b treatment of patients with melanoma. Journal of Cancer Research and Clinical Oncology 2011 137 455 462
60. Singh R. K., Varney M. L., Regulation of interleukin 8 expression in human malignant melanoma cells. Cancer Research 1998 58 7 1532 1537 2-s2.0-0032053795 (Pubitemid 28193620)
61. Palmer K. J., Harries M., Gore M. E., Collins M. K. L., Interferon-alpha (IFN- ) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte turnout cultures (MLTC). Clinical and Experimental Immunology 2000 119 3 412 418 2-s2.0-0034020397 (Pubitemid 30146335)
62. McMillan T. J., Rao J., Everett C. A., Hart I. R., Interferon-induced alterations in metastatic capacity, class-1 antigen expression and natural killer cell sensitivity of melanoma cells. International Journal of Cancer 1987 40 5 659 663 2-s2.0-0023513251 (Pubitemid 18003856)
63. Basham T. Y., Bourgeade M. F., Creasey A. A., Merigan T. C., Interferon increases HLA synthesis in melanoma cells: interferon-resistant and -sensitive cell lines. Proceedings of the National Academy of Sciences of the United States of America 1982 79 10 3265 3269 2-s2.0-0020288361 (Pubitemid 12008387)
64. Giacomini P., Fraioli R., Calabro A. M., Di Filippo F., Natali P. G., Class I major histocompatibility complex enhancement by recombinant leukocyte interferon in the peripheral blood mononuclear cells and plasma of melanoma patients. Cancer Research 1991 51 2 652 656 2-s2.0-0026057239
65. Nistico P., Tecce R., Giacomini P., Cavallari A., D'Agnano I., Fisher P. B., Natali P. G., Effect of recombinant human leukocyte, fibroblast, and immune interferons on expression of class I and II major histocompatibility complex and invariant chain in early passage human melanoma cells. Cancer Research 1990 50 23 7422 7429 2-s2.0-0025667242
66. Maio M., Gulwani B., Langer J. A., Kerbel R. S., Duigou G. J., Fisher P. B., Ferrone S., Modulation by interferons of HLA antigen, high-molecular-weight melanoma-associated antigen, and intercellular adhesion molecule 1 expression by cultured melanoma cells with different metastatic potential. Cancer Research 1989 49 11 2980 2987 2-s2.0-0024313345 (Pubitemid 19148636)
67. Dunn I. S., Haggerty T. J., Kono M., Durda P. J., Butera D., Macdonald D. B., Benson E. M., Rose L. B., Kurnick J. T., Enhancement of human melanoma antigen expression by IFN- β Journal of Immunology 2007 179 4 2134 2142 2-s2.0-34848920859
68. Farkas A., Kemény L., Interferon-in the generation of monocyte-derived dendritic cells: recent advances and implications for dermatology. The British Journal of Dermatology 2011 165 2 247 254 2-s2.0-79960644751 10.1111/j.1365-2133.2011.10301.x
69. Huangfu W. C., Qian J., Liu C., Liu J., Lokshin A. E., Baker D. P., Rui H., Fuchs S. Y., Inflammatory signaling compromises cell responses to interferon alpha. Oncogene 2012 31 2 161 172 2-s2.0-84855769864 10.1038/onc.2011.221
70. Wang W., Edington H. D., Rao U. N. M., Jukic D. M., Land S. R., Ferrone S., Kirkwood J. M., Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFN2b. Clinical Cancer Research 2007 13 5 1523 1531 2-s2.0-33947423447 10.1158/1078-0432.CCR-06-1387 (Pubitemid 46450444)
71. Kirkwood J. M., Farkas D. L., Chakraborty A., Dyer K. F., Tweardy D. J., Abernethy J. L., Edington H. D., Donnelly S. S., Becker D., Systemic interferon-(IFN- ) treatment leads to Stat3 inactivation in melanoma precursor lesions. Molecular Medicine 1999 5 1 11 20 2-s2.0-0033047725 (Pubitemid 29282093)
72. Simons D. L., Lee G., Kirkwood J. M., Lee P. P., Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients. Journal of Translational Medicine 2011 9, article 52 2-s2.0-79955561959 10.1186/1479-5876-9-52
73. Aoyagi S., Hata H., Homma E., Shimizu H., Sequential local injection of low-dose interferon-beta for maintenance therapy in stage II and III melanoma: a single-institution matched case-control study. Oncology 2012 82 3 139 146 2-s2.0-84858320765 10.1159/000336490
74. Schiller J. H., Storer B., Bittner G., Willson J. K. V., Borden E. C., Phase II trial of a combination of interferon- β (ser) and interferon- γ in patients with advanced malignant melanoma. Journal of Interferon Research 1988 8 5 581 589 2-s2.0-0023805049